At the same time, NCTD downregulates the tumor PD‐L1 expression via the β‐catenin pathway, counters Pt drug‐induced PD‐L1 overexpression, and disrupts the PD‐1/PD‐L1 interactions with CTLs, synergistically promoting the CTL activities and antitumor immune responses. Here, CD274 is linked to neoplasm.